

Journal of Visualized Experiments

High throughput quantitative expression screening and purification applied to recombinant disulfide-rich venom proteins produced in *E. coli* --Manuscript Draft--

Manuscript Number:	JoVE51464R3
Full Title:	High throughput quantitative expression screening and purification applied to recombinant disulfide-rich venom proteins produced in <i>E. coli</i>
Article Type:	Invited Methods Article - JoVE Produced Video
Keywords:	<i>E. coli</i> ; expression; recombinant; high throughput (HTP); purification; auto-induction; immobilized metal affinity chromatography (IMAC); tobacco etch virus protease (TEV) cleavage; disulfide bond isomerase C (DsbC) fusion; disulfide bonds; animal venom proteins/peptides.
Manuscript Classifications:	10.1.897.104.416: Automation, Laboratory; 4.12.776.828: Recombinant Proteins; 8.1.158.201.636: Molecular Biology; 8.1.158.550: Biotechnology; 95.51.6: biochemistry
Corresponding Author:	Renaud Vincentelli, ph.D AFMB-UMR CNRS 7257 MARSEILLE, PACA FRANCE
Corresponding Author Secondary Information:	
Corresponding Author E-Mail:	Renaud.Vincentelli@afmb.univ-mrs.fr
Corresponding Author's Institution:	AFMB-UMR CNRS 7257
Corresponding Author's Secondary Institution:	
First Author:	Natalie J Saez, ph. D
First Author Secondary Information:	
Other Authors:	Natalie J Saez, ph. D Hervé Nozach, ph. D Marilyne Blémont
Order of Authors Secondary Information:	
Abstract:	<p><i>Escherichia coli</i> (<i>E. coli</i>) is the most widely used expression system for the production of recombinant proteins for structural and functional studies. However, purifying proteins is sometimes challenging since many proteins are expressed in an insoluble form. When working with difficult or multiple targets it is therefore recommended to use high throughput (HTP) protein expression screening on a small scale (1-4 ml cultures) to quickly identify conditions for soluble expression. To cope with the various structural genomics programs of the lab, a quantitative (within a range of 0.1-100 mg/L culture of recombinant protein) and HTP protein expression screening protocol was implemented and validated on thousands of proteins. The protocols were automated with the use of a liquid handling robot but can also be performed manually without specialized equipment.</p> <p>Disulfide-rich venom proteins are gaining increasing recognition for their potential as therapeutic drug leads and insecticides. They can be highly potent and selective, but their complex disulfide bond networks make them challenging to produce. As a member of the FP7 European Venomics project (www.venomics.eu), our challenge is to develop successful production strategies with the aim of producing thousands of novel venom proteins for functional characterization. Aided by the redox properties of disulfide bond isomerase DsbC, we adapted our HTP production pipeline for the expression of oxidized, functional venom peptides in the <i>E. coli</i> cytoplasm. The protocols are also applicable to the production of diverse disulfide-rich proteins. Here we demonstrate our pipeline applied to the production of animal venom proteins. With</p>

	the protocols described herein it is likely that soluble disulfide-rich proteins will be obtained in as little as a week. Even from a small scale, there is the potential to use the purified proteins for validating the oxidation state by mass spectrometry, for characterization in pilot studies, or for sensitive micro-assays.
Author Comments:	
Additional Information:	
Question	Response

Dr Renaud Vincentelli
AFMB UMR 7257
Campus de Luminy
Case 932
163, avenue de Luminy
13288 MARSEILLE Cedex 09
France
renaud.vincentelli@afmb.univ-mrs.fr

Marseille, 29th of July 2013.

Dear JoVE editors,

Please find enclosed a manuscript entitled “High throughput cloning, quantitative expression screening and analytical affinity purification of disulfide-rich proteins and peptides in *E. coli*”, as previously requested by JoVE editor Nandita Singh. The protocol describes a redox-active fusion strategy for the expression of disulfide-bonded targets at the small scale to identify constructs yielding soluble protein after affinity purification (and optional cleavage). The expression of disulfide-bonded proteins and peptides in *E. coli* is still considered challenging, and we hope that with these protocols, the expression of such proteins will become less daunting and more accessible to a wider range of researchers. We currently use the protocols herein for the expression of disulfide-rich venom peptides as part of the FP7 European VENOMICS Project and representative results are provided for targets from this project.

We believe that this work fits very well with the video format of JoVE. The high throughput protocols described in this article utilize robotics and the video will better demonstrate the simplicity and eloquence of the techniques than several pages of text explaining the various steps and details of the procedures.

Of the four authors contributing to this manuscript, all have been involved in the previous experimental work allowing the development and compilation of the protocols herein. HN and MB cloned the destination plasmids; NS and RV designed and supervised the high throughput experiments; NS, HN, MB and RV have performed the high throughput recombinant expression screening experiments; HN and MB have performed scale-up validation of the expression and purification results at small-scale. NS and HN have performed mass spectroscopy experiments; All authors have analyzed data and contributed to the writing of the manuscript. The final manuscript (and the accompanying video to be produced by JoVE) has been approved by all authors, as well as the associated VENOMICS Consortium.

We suggest the following people for the peer review of this article:

Imre Berger
iberger@embl.fr

European Molecular Biology Laboratory,
France

Joop Van den Heuvel
Joop.VandenHeuvel@helmholtz-hzi.de

Helmholtz-Zentrum für Infektionsforschung,
Germany

Ray Owens
ray@strubi.ox.ac.uk

Oxford Protein Production Facility, UK

Glenn F. King
glenn.king@imb.uq.edu.au

Institute for Molecular Bioscience, Australia

Bill Gillette
gillettew@mail.nih.gov

Frederick National Laboratory for Cancer
Research, USA

Jean-Denis Pedelacq
Jean-Denis.Pedelacq@ipbs.fr

Institute of Pharmacology and Structural
Biology, France

Thank you for taking the time to consider our submission.

Sincerely,

Natalie J. Saez and Renaud Vincentelli

TITLE: High throughput quantitative expression screening and purification applied to recombinant disulfide-rich venom proteins produced in *E. coli*

AUTHORS:

Saez, Natalie J
Architecture et Fonction des Macromolécules Biologiques (AFMB)
Aix Marseille Université
Marseille, France
Natalie.Saez@afmb.univ-mrs.fr

Nozach, Hervé
iBiTec-S, Service d'Ingénierie Moléculaire des Protéines (SIMOPRO)
Commissariat à l'énergie atomique et aux énergies alternatives (CEA) Saclay
Gif sur Yvette, France
herve.nozach@cea.fr

Blemont, Marilyne
Architecture et Fonction des Macromolécules Biologiques (AFMB)
Aix Marseille Université
Marseille, France
Marilyne.Blemont@afmb.univ-mrs.fr

Vincentelli, Renaud
Architecture et Fonction des Macromolécules Biologiques (AFMB)
Aix Marseille Université
Marseille, France
Renaud.Vincentelli@afmb.univ-mrs.fr

CORRESPONDING AUTHOR:

Vincentelli, Renaud
Architecture et Fonction des Macromolécules Biologiques (AFMB)
Aix Marseille Université
Marseille, France
Renaud.Vincentelli@afmb.univ-mrs.fr

KEYWORDS:

E. coli, expression, recombinant, high throughput (HTP), purification, auto-induction, immobilized metal affinity chromatography (IMAC), tobacco etch virus protease (TEV) cleavage, disulfide bond isomerase C (DsbC) fusion, disulfide bonds, animal venom proteins/peptides.

SHORT ABSTRACT:

A protocol for the quantitative, high throughput expression screening and analytical purification of fusion proteins from small-scale *Escherichia coli* cultures is described and applied to the expression of disulfide-rich animal venom protein targets.

LONG ABSTRACT:

Escherichia coli (*E. coli*) is the most widely used expression system for the production of recombinant proteins for structural and functional studies. However, purifying proteins is sometimes challenging since many proteins are expressed in an insoluble form. When working with difficult or multiple targets it is therefore recommended to use high throughput (HTP) protein expression screening on a small scale (1-4 ml cultures) to quickly identify conditions for soluble expression. To cope with the various structural genomics programs of the lab, a quantitative (within a range of 0.1–100 mg/L culture of recombinant protein) and HTP protein expression screening protocol was implemented and validated on thousands of proteins. The protocols were automated with the use of a liquid handling robot but can also be performed manually without specialized equipment.

Disulfide-rich venom proteins are gaining increasing recognition for their potential as therapeutic drug leads and insecticides. They can be highly potent and selective, but their complex disulfide bond networks make them challenging to produce. As a member of the FP7 European Venomics project (www.venomics.eu), our challenge is to develop successful production strategies with the aim of producing thousands of novel venom proteins for functional characterization. Aided by the redox properties of disulfide bond isomerase DsbC, we adapted our HTP production pipeline for the expression of oxidized, functional venom peptides in the *E. coli* cytoplasm. The protocols are also applicable to the production of diverse disulfide-rich proteins. Here we demonstrate our pipeline applied to the production of animal venom proteins. With the protocols described herein it is likely that soluble disulfide-rich proteins will be obtained in as little as a week. Even from a small scale, there is the potential to use the purified proteins for validating the oxidation state by mass spectrometry, for characterization in pilot studies, or for sensitive micro-assays.

INTRODUCTION:

Motivated by the advancement of genomics and accelerated rate of discovery of new proteins, high throughput pipelines have been developed to parallelize traditional approaches for the screening and identification of optimal protein production strategies. Potential variables to be optimized include, but are not limited to, varying expression strains^{1,2}, temperature^{3,4}, media^{2,3}, target variants⁵, fusion partners⁶⁻¹³, co-expression with chaperones^{14,15}, cytoplasmic or periplasmic expression¹⁶⁻¹⁸ and purification buffer components³. By implementing high throughput approaches, many variables or many targets can be tested in parallel with a high level of efficiency, while limiting batch-to-batch variation. In our experience, the strategy also

gives good reproducibility upon scale-up using the same culture (temperature, media, aeration etc.) and purification conditions (same resin, buffers etc.). Several high throughput platforms have been used in the past decade to identify conditions for soluble protein expression, namely through varying parameters such as fusion partners, expression strains or temperature¹⁹⁻²³.

We recently used our high throughput screening approach for the expression of soluble disulfide-rich proteins¹¹. The proteins selected were not only from venomous sources, but also included disulfide-rich enzyme inhibitors from a wide range of species including plants, pigs, cows and humans. The experiment compared the effects of 12 different fusion partners and three different expression strains on the solubility and folding of 28 disulfide-reticulated proteins. We demonstrated that using DsbC as a fusion partner for production in the strain BL21 (DE3) pLysS vastly outproduced (in both yield and number of soluble proteins obtained) any other combination of strain and fusion tested¹¹. The results of this experiment formed the basis for adapting our original general high throughput pipeline (which has been used for the expression screening of a wide range of proteins)^{22,24} into one more suited for the expression of disulfide-rich targets. Disulfide-rich proteins from animal venoms are of particular interest. Venoms are a complex mixture of bioactive peptides and proteins, with potential value pharmacologically and therapeutically. However, expression of disulfide bond-containing proteins is not trivial. These proteins generally contain between one to seven disulfide bonds, and must be oxidized with the correct disulfide-bonding patterns in order to be active. Currently, the platform is being used for screening the expression of a large number of disulfide-rich animal venom proteins as part of the FP7 European VENOMICS Project (www.venomics.eu) and benchmarking novel protocols for the high throughput expression of thousands of targets. Here, an automated method is provided for high throughput small-scale expression screening and purification (see Figure 1) applied to disulfide-rich animal venom proteins. The strategy for disulfide rich peptides and proteins utilizes a HIS-tag for purification and the redox-active fusion partner, DsbC, creating cleavable HIS-DsbC fusions to the target proteins (see Figure 2).

While the focus of the protocols herein is automation using a liquid handling robot and HTP electrophoresis, these methods are also suitable for a high throughput manual approach, meaning that even laboratories with a basic setup can take advantage of the protocols without any prerequisite for expensive equipment. Manual protocols for the transformation to purification and analysis (not specific to disulfide-rich proteins) have been published elsewhere²⁴ and will not be repeated here. The throughput of the manual procedure (from expression clone, produced by recombinational cloning²⁵, to analysis of soluble protein levels) is 96 (using SDS-PAGE detection) or 384 (4 x 96; using dot blot and SDS-PAGE²⁶) cultures per week (see Figure 1). This can be increased if performed in a semi-automated way (using a liquid handling robot and dot blot²⁶ or HTP electrophoresis, such as with a Caliper GXII LabChip system²² for analysis of results) to up to 1152 (12 x 96) cultures in parallel over one week, as described herein. Culturing is performed in deep well 24 (DW24) format so that regular shaking incubators can be used in contrast to cultures grown in deep well 96 (DW96) format, which necessitate the use of short orbital high-speed shaking incubators for sufficient aeration (shaking at 800 rpm). The use of auto-induction media²⁷ also simplifies expression, eliminating

the manual induction step. Even where laboratories already use pre-defined expression and purification conditions, these can be transferred directly into this HTP system simply to improve efficiency. A detailed schematic of the high throughput screening pipeline for disulfide-rich proteins is provided in Figure 3. The parameters in the pipeline were selected based on extensive screening experiments^{11,22}, which allowed us to choose the most useful conditions for protein production.

Characterization can be performed on tagged proteins purified directly from small-scale expressions in pilot studies where tens of micrograms of sample is sufficient, or for sensitive functional assays and binding assays (for example, low volume HTP patch clamp systems²⁸). The same can even be performed on the untagged targets after cleavage, provided the tag and protease are removed (for example, by reverse phase HPLC). Quality control can also be performed by mass spectrometry (to confirm the expected size and oxidation state) or chromatographic methods (to confirm purity or heterogeneity)²⁹. Sometimes tag cleavage is unnecessary or even undesirable (particularly for poorly soluble proteins^{30,31}), so in this protocol cleavage is optional. Regardless, in all constructs there is a TEV protease cleavage site (ENLYFQ/[G]³²) directly preceding the target gene to produce native protein after cleavage (see Figure 2 and Discussion). If cleavage of the fusion tag is desired, cleavage can be tested (on the elution fraction or 'on column') at the small scale to analyze efficiency, optimize conditions if required and obtain reliable estimates of yields for subsequent scale-up experiments.

There are two options for the volume of beads used during the affinity purification, depending on the aims and expectations of the experiment. To be able to capture as much protein as possible (to purify for pilot assays or MS, or to extrapolate for scale-up yields) a final volume of 200 µl of resin should be used, allowing detection of soluble protein in the range of 1–100 mg/L culture before saturation of the system (see protocol (A) in Section 8.1). However, if the aim of the experiment is the detection of low amounts of soluble proteins then a final volume of 50 µl of resin is suitable, allowing detection of soluble protein in the range of 0.1–25 mg/L culture (see protocol (B) in Section 8.2).

Production can be scaled up, if required, to obtain milligram quantities of purified targets for further structural and functional studies using the conditions identified for soluble expression. The details of scale-up protocols used at AFMB have been discussed elsewhere^{22,24}.

Further details relevant to the experimental setup, critical steps within the protocol, modifications and trouble-shooting and limitations of the technique are provided in the discussion. Please read the discussion before commencing the experiments.

Throughout the protocols we expect a success rate of 90% at each step (for example, at least 90% of the cultures must grow at any given step). If the success rate of any step in the experiment falls below 90% the samples are discarded and the experiment is repeated for the full collection of constructs. However, this success rate is not applicable to the number of constructs that express as soluble proteins or the proportion of constructs that cleave with 100% efficiency, as this will be highly dependent on the proteins tested.

The specific details for the set-up of the robot worktable are provided for each protocol (also see Figure 4), however they can be adapted as required for alternative worktable set-ups. The robot hardware (Tecan) consists of a 96-multichannel arm (MCA96), robotic manipulator (RoMa) and the 8-channel liquid handling head (LiHa). All steps utilizing the MCA96 can also be performed using the LiHa if an MCA96 is not available, however they will take longer because the LiHa will need to be washed between steps. While the robot is technically not a sterile environment, the inclusion of antibiotics generally ensures that there are not problems with contamination or sterility.

PROTOCOL:

PART A: TRANSFORMATION AND TEST EXPRESSION

Manual procedures for cloning²² and transformation to purification are discussed elsewhere²⁴. The transformation protocol can be fully performed on the robot²⁶ but it is usually more time-efficient to do it manually. Therefore the protocols herein begin from inoculation of the expression precultures and plating of the transformation from the heat shocked transformation mixes done manually. For further details on the manual cloning and transformation procedures see the relevant references^{22,24}.

1. Precultures and plating

1.1) Prepare the robot worktable (see Figure 4 for positions):

1.1.1) Put a 300 ml trough containing 150 ml sterile LB broth (supplemented with Ampicillin (100 µg/ml)/Chloramphenicol (34 µg/ml), or other appropriate antibiotic) at position 8.

1.1.2) Put a sterile DW96 at position 11. Put 4 x pre-prepared 24-well LB agar (Amp/Cam) tissue culture plates (containing 2 ml agar in each well) with their lids on in positions 14 to 17.

1.1.3) Put the transformation plate (containing the 96 transformation mixes after heatshock) at position 13. This will be used to inoculate the liquid precultures and LB agar plates. Put a box of sterile 200 µl pipette tips at position 18.

1.2) Using the 96-multichannel arm (MCA96) and 200 µl tips, aspirate 200 µl of LB broth (position 8) and dispense into the DW96 at position 11. Repeat until there is a final volume of 1 ml LB broth in each well of the DW96. This will become the liquid preculture.

1.3) Using the robotic manipulator (RoMa), remove the lid of the first 24-well LB agar plate and place it elsewhere (for example in a hotel carrier) until the plating is finished for that plate.

1.4) Using the 8-channel liquid handling (LiHa) head, aspirate 50 µl of the first column of transformation mix at position 13. This volume of transformation mix is just enough to cover the LB-Agar well.

1.5) With the first 4 channels, dispense onto the first column of the first 24-well LB agar plate at position 14 (as shown in Figure 5).

1.6) With the last 4 channels, dispense onto the second column of the first 24-well LB agar plate.

1.7) Wash all tips thoroughly after dispensing.

1.8) Continue this process until all transformations have been plated on the first plate at position 14, transferring from 96- to 24-well using the scheme provided in Figure 5.

1.9) Once the first plate has been completed, use the RoMa to replace the lid and remove the lid from the next plate at position 15. Continue using the plating scheme for the next 3 plates.

1.10) Once plating is finished, set the Te-Shake to 1200 rpm and shake all plates for 1 min to have a homogenous distribution of the transformation mix.

1.11) Using the MCA96 and the original pipette tips, aspirate 60 μ l of the remaining transformation mix (position 13) and dispense into the DW96 containing LB broth at position 11.

1.12) Seal the DW96 precultures with breathable adhesive film to allow culture aeration.

1.13) Place in a 37 °C shaking incubator at maximum speed overnight (200/800 rpm depending on shaker orbital).

1.14) The LB agar plates should be placed in a hood with their lids off until dry (10 minutes). Then they are placed inverted in a 37 °C plate incubator until the following morning.

1.15) The next day, the preculture is used to inoculate the test expression in auto-induction medium and for preparation of glycerol stocks. Put the agar plates in a refrigerator, as a back up. If necessary, starting from the agar plates or the glycerol stocks, the test expression could be re-done by inoculating a fresh LB preculture directly.

2. Preparation of DW24 ZYP-5052 plates

NOTE: This procedure takes approximately 5 mins to complete for each set of 4 x DW24 plates.

2.1) Make up 500 ml ZYP-5052 auto-induction medium for each replicate of 96 cultures (464 ml ZY medium, 250 μ l 2M MgSO_4 , 10 ml 50X 5052, 25 ml 20X NPS, in that order – the recipes for each component are provided in Table 1) supplemented with the appropriate antibiotics.

2.2) Prepare the robot worktable:

2.2.1) Put two 300 ml troughs, each containing ~250 ml medium at position 5 and 6. Put four sterile DW24 plates at positions 14 to 17. Put 200 µl tips at position 18.

2.3) Using the MCA96 and 200 µl tips, aspirate 200 µl of ZYP-5052 from position 5 and dispense into the first DW24 plate at position 14. Do this a total of 5 times (4 tips will dispense into a single well at once for a total of 4 ml). Repeat for the remaining 3 x DW24 plates at positions 15 to 17, switching to the ZYP-5052 at position 6 for the last two DW24 plates.

3. Inoculation and growth of the test expression cultures

NOTE: Inoculation takes approximately 10 mins to complete for each set of 4 x DW24 plates, and growth continues overnight.

3.1) Prepare the robot worktable:

3.1.1) Put the DW96 plate containing the precultures (from step 1.15) at position 11. Put the four DW24 plates containing ZYP-5052 medium (from step 2.3) at positions 14 to 17.

3.2) Using the LiHa aspirate 100 µl of preculture from position 11 to inoculate the test expression cultures (1/40 dilution) using the scheme provided in Figure 5. Wash the LiHa head thoroughly at the wash station between each column of the 96-well precultures.

3.3) Seal the DW24 plates with breathable film and incubate at 37 °C with shaking (200 rpm) for 4 hrs. This is the time of the growth phase during which glucose from the medium will preferentially be depleted²⁷.

3.4) Reduce the temperature to 17 °C. After the 4 hrs and depletion of glucose, lactose will start to be metabolized, leading to induction of expression, providing the optimal growth conditions for BL21 (DE3) pLysS or Rosetta 2 (DE3) pLysS, in this work²². Leave the cells to express overnight. Use the remaining preculture to make glycerol stocks.

4. Preparation of glycerol stocks

NOTE: Glycerol stocks should be made in triplicates to be stored in different locations in case of freezer failure.

4.1) Prepare the robot worktable:

4.1.1) Put microtiter plates at position 5 to 7 to house the glycerol stocks. Put a 300 ml trough filled with 50 ml of 100% glycerol at position 8. Put a DW96 containing 800 µl of preculture (after step 3.2) in each well at position 11. Put 200 µl tips at position 18.

4.2) Using a slow aspiration and dispensing speed, use the MCA96 and 200 µl tips to add glycerol into the DW96 containing the precultures.

4.2.1) Aspirate 200 µl of glycerol (from position 8).

4.2.2) Dispense 150 μ l (at position 11) first, then pause for 20 secs to allow the remaining glycerol to reach the bottom of the tip. Dispense the remaining 50 μ l.

4.3) Using the same tips, mix the culture and glycerol in the DW96 at position 11 until they are thoroughly mixed. The final concentration of glycerol is 20%. Aspirate 140 μ l from the DW96 and dispense into the first microtiter plate at position 5.

4.4) Repeat step 4.3 for each remaining microtiter plate (positions 6 and 7).

4.5) Seal each microtiter plate with plastic adhesive tape and store at -80 °C. Discard the remaining culture in the DW96, decontaminating with an antimicrobial agent before disposal.

5. Assessing the growth of the cultures

NOTE: It is not usually necessary to assess the final growth rate as the final OD_{600nm} is usually the same for most cultures (around 12 in these conditions), however any cultures that do not grow should be noted.

5.1) Take 50 μ l of each culture (from step 3.4) and dispense into a flat-bottomed, clear microtiter plate containing 150 μ l of medium.

5.2) Measure the OD_{600nm}, taking into account the 4-fold dilution. If there are any that did not grow very well, note this for the final analysis.

6. Harvesting the cells

NOTE: This procedure takes approximately 45 mins to complete.

6.1) Centrifuge the 4 x DW24 plates (from step 3.4) at 3800 x *g* for 10 mins then discard the supernatant into a waste container containing antimicrobial agent. Tap the plates, upside-down, onto absorbent paper to remove any excess medium.

6.2) In the meantime, prepare 100 ml of lysis buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole pH 8, or other preferred buffer) containing lysozyme (final concentration 0.25 mg/ml).

6.3) Prepare the robot worktable:

6.3.1) Put the lysis buffer in a 300 ml trough at position 5. Put a clean DW96 at position 11. Put the 4 x DW24 plates containing the cell pellets (from step 6.1) in positions 14–17. Put 200 μ l tips at position 18.

6.4) Using the MCA96 and 200 μ l tips, aspirate 125 μ l of lysis buffer from position 5 and dispense into each DW24 plate (positions 14–17). Repeat. NOTE: 4 tips will dispense into a single well at once for a final volume of 1 ml in each well of the DW24 plates.

6.5) Shake the plates at positions 14–17 using the Te-Shake (200 rpm) for 15 mins to resuspend the pellets.

6.6) Once the pellets are resuspended, use the first 4 channels of the LiHa to aspirate 550 µl from samples 1 to 4 (the first column of the first DW24, at position 14), then using the last 4 channels of the LiHa aspirate 550 µl of samples 5 to 8 (the second column of the first DW24). Dispense into the first row of the DW96 at position 11.

6.7) Repeat step 6.6, so that all of the cell suspension is transferred to the DW96.

6.8) After each set of samples wash the LiHa tips in the wash station.

6.9) Repeat steps 6.6 to 6.8 for each column in each DW24 plate (positions 15–17) using the scheme provided in Figure 5. Seal with plastic film.

6.10) For purification on the same day or short-term freezing, store at -80 °C for a minimum of 1 hr, otherwise store at -20 °C.

PART B: PURIFICATION AND ANALYSIS

7. Cell lysis

NOTE: This procedure takes around 60 mins to complete.

7.1) Thaw the frozen cell suspensions (from step 6.10) in a water bath (at room temperature or 37 °C) for approximately 15 mins and resuspend in the shaking incubator for an additional 10 mins. The cultures should become **viscous**.

7.2) Take 500 µl of DNase stock and mix it with 1 ml of MgSO₄ stock. Manually with an 8-channel pipette or with the robot LiHa, dispense 15 µl into each well of the DW96, to give a final concentration of 10 µg/ml of DNase and 20 mM MgSO₄.

7.3) Re-seal the plate with plastic tape and shake for a further 15 mins. At this point the cultures should be **non-viscous**. Check carefully (by visual examination) that all the cultures are no longer viscous. NOTE: This is **critical**, if some cultures are still viscous (for example, if the DNase was accidentally forgotten or not dispensed appropriately in some wells), the filter will clog, generating an uneven pressure on the samples and overflow or total clogging of the filter plate could happen during the purification.

7.4) For SDS-PAGE samples of the whole cell lysate, aspirate 10 µl of lysate and dispense into a 96-well PCR plate containing 10 µl of 4X SDS-PAGE sample buffer and 20 µl of water. Denature for 3 mins at 95 °C and freeze until analysis (Total fraction). If a HTP electrophoresis system is available, the samples can be analyzed on this instead following the Manufacturer's

recommended protocol for sample preparation. For further details regarding analysis of the samples see Section 10.

8. Ni affinity purification

NOTE: A slow aspiration speed should be used for pipetting all resin suspensions, as the suspensions are quite thick. Over-drying the resin will result in a reduction in binding capacity. For purification, the specified imidazole concentrations are applicable to nickel affinity resin. If alternative ions (eg. cobalt) are used, then the concentrations should be adjusted accordingly.

8.1. A - Ni affinity purification for detection in the range of 1–100 mg/L (final resin volume = 200 µl)

NOTE: This purification procedure takes around 1.5 hrs to complete, meaning that up to 4 can be performed in one day.

8.1.1) Prepare the robot worktable:

8.1.1.1) Put 300 ml troughs containing binding buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole pH 8), wash buffer (50 mM Tris, 300 mM NaCl, 50 mM imidazole pH 8) and elution buffer (50 mM Tris, 300 mM NaCl, 250 mM imidazole pH 8) in positions 6 to 8, respectively.

8.1.1.2) Leave an empty 300 ml trough at position 5 for the resin slurry. At position 9 and 10 put plate holders. At position 10 put a DW96 with the SPE block and filter/receiver plate (20 µm) on top.

8.1.1.3) Put the DW96 containing the lysate (from step 7.3) at position 14. At position 18 and 19 put the 200 µl wide bore tips and 200 µl tips, respectively. Put two spare DW96 plates for the wash and elution in a hotel. NOTE: They could also be put at an alternative site on the worktable if a hotel is unavailable.

8.1.2) Prepare 105 ml of equilibrated 33% resin slurry (35 ml resin + 70 ml binding buffer). Add the resin suspension to the trough at position 5 immediately before beginning the procedure.

8.1.3) Using the MCA96 and 200 µl wide bore tips (position 18), mix the resin slurry at position 5 thoroughly before aspirating and dispensing 200 µl of resin slurry into the DW96 containing the lysate at position 14. Repeat twice so that 600 µl of resin slurry has been added to the lysate, mixing the resin suspension before each aspiration.

8.1.4) Perform a 10 min mixing step using the MCA96 at position 14 to allow for binding and to prevent the resin from pelleting.

8.1.5) Aspirate from position 14 and dispense 800 µl (in 200 µl lots) onto the filter plate at position 10, mixing before each aspiration otherwise the resin will be retained at the bottom of the DW96.

8.1.6) Turn the vacuum on at position 10 for approximately 90 secs to filter the lysate through the plate into the DW96 to collect the flow-through, taking care not to dry out the resin. Turn the vacuum off.

8.1.7) Repeat steps 8.1.5 and 8.1.6 so that all of the resin is then in the filter plate.

8.1.8) Using the RoMa arm move the SPE block holding the filter plate from position 10 to position 9 so that the next wash step goes directly to the waste and transfer the DW96 containing the flow-through at position 10 to another site (e.g. into a hotel carrier) until the end of the procedure.

8.1.9) With a new set of 200 µl tips (at position 19), wash the resin (at position 9) with a total of 800 µl of binding buffer (from position 6), and apply the vacuum at position 9 until the buffer has passed through. Repeat once more.

8.1.10) Use the RoMa arm to place a fresh DW96 at position 10 to collect the 50 mM imidazole wash and move the SPE block and filter plate back on top (position 10).

8.1.11) Add 800 µl of wash buffer from position 7 onto position 10, turn the vacuum on until the buffer has passed through. Switch the vacuum off.

8.1.12) With the ROMA, remove the SPE block and filter plate to position 9 and the DW96 containing the wash sample to the hotel, and keep it aside until the end of the procedure.

8.1.13) Wash the resin with another 800 µl of wash buffer (from position 7 onto position 9), apply the vacuum until the buffer has passed through. Repeat once more.

8.1.14) Use the RoMa to place a fresh DW96 at position 10 and place the SPE block and filter plate back on top to collect the elution.

8.1.15) Add a total of 500 µl of elution buffer (from position 8 onto position 10) and incubate *in situ* for 3 mins. Turn on the vacuum until all buffer has passed through.

8.1.16) Optional: For highly expressing proteins, a second elution can be performed into a fresh DW96 as in steps 8.1.14 and 8.1.15.

8.1.17) Take samples of the flow-through, wash and elution/s for SDS-PAGE or HTP electrophoresis.

8.1.17.1) For SDS-PAGE samples of the flow-through, dispense 10 µl into a 96-well PCR plate containing 10 µl of 4X SDS-PAGE sample buffer and 20 µl of water. For SDS-PAGE samples of the wash and elution/s dispense 30 µl into PCR plates containing 10 µl of 4X SDS-PAGE sample buffer. Denature for 3 mins at 95°C and freeze until analysis.

8.1.17.2) For HTP electrophoresis samples, follow the manufacturer's instructions. For further details regarding analysis of the samples see Section 10.

8.2. *B - Ni affinity purification for detection in the range of 0.1–25 mg/L (final resin volume = 50 µl)*

NOTE: This purification procedure takes around 30 mins to complete, meaning that up to 12 can be performed in one day.

8.2.1) Prepare the robot worktable:

8.2.1.1) Put 300 ml troughs containing binding buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole pH 8), wash buffer (50 mM Tris, 300 mM NaCl, 50 mM imidazole pH 8) and elution buffer (50 mM Tris, 300 mM NaCl, 250 mM imidazole pH 8) in positions 6 to 8, respectively.

8.2.1.2) Leave an empty 300 ml trough at position 5 for the resin slurry. At position 9 and 10 put plate holders. At position 10 put a DW96 with the SPE block and filter/receiver plate (20 µm) on top.

8.2.1.3) Put the DW96 containing the lysate (from step 7.3) at position 14. At position 18 and 19 put 200 µl wide bore tips and 200 µl tips, respectively. Put a spare 96-well microtiter plate for the elution in a hotel. NOTE: This could also be put at an alternative site on the worktable if a hotel is unavailable.

8.2.2) Prepare 50 ml of equilibrated 25% resin slurry (12.5 ml resin + 37.5 ml binding buffer). Add the resin suspension to the trough at position 5 immediately before beginning the procedure.

8.2.3) Using the MCA96 and 200 µl wide bore tips (position 18), mix the resin slurry at position 5 thoroughly before aspirating and dispensing 200 µl of resin slurry into the DW96 containing the lysate at position 14.

8.2.4) Incubate at room temperature with shaking using the Te-Shake at 1400 rpm for 10 mins to allow binding.

8.2.5) Aspirate from position 14 and dispense the full 1200 µl (in 200 µl lots) using the wide bore tips (position 18) onto the filter plate at position 10. Mix before each aspiration otherwise the resin will be retained at the bottom of the DW96.

8.2.6) Turn the vacuum on at position 10 for approximately 30 secs to filter the lysate through the plate into the DW96 to collect the flow-through, taking care not to dry out the resin. Turn the vacuum off.

8.2.7) Using the RoMa arm, move the SPE block holding the filter plate from position 10 to position 9 so that the next wash step goes directly to the waste and transfer the DW96 containing the flow-through at position 10 to another site (e.g. into a hotel carrier) until the end of the procedure.

8.2.8) With the 200 µl tips (at position 19), wash the resin (at position 9) with a total of 800 µl of binding buffer (from position 6), and apply the vacuum at position 9 until the buffer has passed through. Repeat.

8.2.9) Use the RoMa arm to place the fresh DW96 at position 10 to collect the 50 mM imidazole wash and move the SPE block and filter plate back on top (position 10).

8.2.10) Add 150 µl of wash buffer from position 7 onto position 10, turn the vacuum on until the buffer has passed through. Switch the vacuum off.

8.2.11) With the ROMA remove the SPE block and filter plate to position 9 and the DW96 containing the wash sample to the hotel, and keep it aside until the end of the procedure.

8.2.12) Wash the resin with another 800 µl of wash buffer (from position 7 onto position 9), apply the vacuum until the buffer has passed through. Repeat.

8.2.13) Use the RoMa to place the microplate at position 10 and place the SPE block and filter plate back on top to collect the elution.

8.2.14) Add 190 µl of elution buffer (from position 8 onto position 10) and incubate *in situ* for 3 mins. Apply the vacuum until all buffer has passed through.

8.2.15) Take samples of the flow-through, wash and elution for SDS-PAGE or HTP electrophoresis.

8.2.15.1) For SDS-PAGE samples of the flow-through, dispense 10 µl into a 96-well PCR plate containing 10 µl of 4X SDS-PAGE sample buffer and 20 µl of water. For SDS-PAGE samples of the wash and elution/s dispense 30 µl into PCR plates containing 10 µl of 4X SDS-PAGE sample buffer. Denature for 3 mins at 95 °C and freeze until analysis.

8.2.15.2) For HTP electrophoresis samples, follow the manufacturer's instructions. For further details regarding analysis of the samples see Section 10.

9. Tag cleavage (optional)

9.1) Add the TEV protease (2 mg/ml) to the eluted protein (from step 8.1.15 (and 8.1.16) or step 8.2.14) in a ratio of 1/10 (v/v).

9.2) Incubate at room temperature (or 4 °C for temperature-sensitive proteins) over-night with gentle shaking.

9.3) At the end of cleavage dispense 30 µl into a PCR plate containing 10 µl of 4X SDS-PAGE sample buffer or follow the Manufacturer's instructions for HTP electrophoresis samples.

9.4) Filter the remaining cleavage mixture (from step 9.2) through a 96-well 0.22 µm filter plate and collect the soluble flow-through in a DW96 by applying the vacuum. This can be done at one of the vacuum sites (eg. position 10) on the liquid handling robot, like for the elution steps in Sections 8.1 and 8.2. This removes any protein that precipitated during cleavage.

9.5) After filtration, dispense 30 µl into a PCR plate containing 10 µl of 4X SDS-PAGE sample buffer or prepare as HTP electrophoresis samples. This allows the comparison of the protein before cleavage, the mixture after cleavage and the soluble protein remaining after cleavage and gives good indications of the expected results in subsequent scale-up experiments. For further details regarding analysis of the samples see Section 10.

10. Analysis of results

10.1) Identify the constructs expressing soluble protein by analyzing the purification samples on SDS-PAGE, dot blot or HTP electrophoresis system such as the Caliper LabChip.

10.1.1) Analyze the elution samples first to identify constructs producing soluble protein. In most cases only the elution samples are analyzed if soluble constructs are identified, to minimize the time spent on the analysis.

10.1.2) If the protein is not in the elution, run the wash and flow-through samples to see if it was expressed and did not bind properly to the resin.

10.1.3) For constructs where no soluble protein can be detected run the whole cell lysate to see if the protein was expressed.

NOTE: One limitation here is that if the protein of interest is not present above background expression levels, it may not be possible to see the protein and could lead to a false negative. It must be noted that it is always possible for proteins to stick and precipitate on the affinity resin and this could lead to a false negative or under-estimation of the yield using the recommended protocol (a rare event in this work). In the event that the protein precipitates upon elution (a white pellet is visible a few minutes/hours after elution) it is recommended to change the buffer composition (for example, salt concentration) and/or perform a differential scanning fluorimetry assay to optimize the buffers. A small sample of the resin can also be resuspended in SDS-PAGE sample buffer and boiled to detect if a protein is being retained on the resin.

10.1.4) If the protein was not expressed but the cells did grow, pursue a new expression strategy, or if the OD_{600nm} was not high enough regrow and reanalyze the culture.

10.1.5) If cleavage samples are to be analyzed, they should be analyzed in a side-by-side manner, so that each construct can be shown before cleavage and after cleavage in adjacent lanes, to simplify the analysis.

10.2) Unless using a method that gives direct quantification of the elution concentration, quantification should be performed for positive samples by measuring the absorbance at 280 nm (A_{280}).

10.2.1) Measure the A_{280} , taking the extinction coefficient of the protein into account and using the elution buffer as a blank, to provide an estimate of protein yield in order to identify the highest expressing soluble constructs.

10.2.2) For the most reliable comparison of soluble yields, it is recommended to normalize the yields by the density of the culture (using the OD_{600nm} measurement), which was taken at Section 5. If all cultures grew to approximately the same density, normalization is not required.

11. Quality control

11.1) Samples can be analyzed directly from the elution or cleavage sample by liquid chromatography–mass spectrometry (LC/MS).

11.2) Alternatively, desalt first (to remove imidazole and any buffer salts that may be present) using ZipTip pipette tips or liquid chromatography methods, then analyze using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or electrospray ionization (ESI) mass spectrometry.

11.3) Small-scale functional studies can be performed to check if the function of the protein is as expected. If larger amounts are required for function, a scale-up culture can be made and the function tested from the larger culture once size and oxidation state have been confirmed at the small scale.

REPRESENTATIVE RESULTS:

Representative results are shown in Figure 6 for the expression screening of 96 disulfide-rich proteins from the VENOMICS pipeline. The proteins are arranged by increasing number of disulfide bonds then increasing number of residues. The peptides were expressed in the cytoplasm with a HIS-tag and DsbC fusion partner. When using the recommended culture conditions, an OD_{600nm} of 12 is normally achieved. The peptides were purified using protocol 8.2-B with a final volume of 50 μ l of nickel affinity resin, so a maximum of ~25 mg/L fusion protein could be detected in this experiment.

Figure 6A shows the electrophoresis result from the Caliper LabChip system (showing the fusion before cleavage) and the scoring system based on extrapolation to yield in mg/L culture of the fusion protein (in levels of 0.1 to 2 mg/L culture, 2 to 10 mg/L culture, 10 to 25 mg/L culture

and not detected.) Note that the cleaved DsbC tag normally runs at around 32 kDa, rather than 27 kDa as expected. Similarly, the DsbC fusions also run around 5 kDa higher than expected. For a lot of the targets we not only see the intact fusion (upper band), but also the fusion partner alone (lower band). For some of these targets optimizing the culture conditions can improve the ratio of the intact fusion (upper band) compared to DsbC alone allowing an increase of the final yield. The scoring is based only on the level of intact fusion. Only 16 out of 96 proteins could not be detected at the fusion level. This corresponds to an overall success level of 83%. Of the 80 proteins that could be detected, 45 of these were detected at levels greater than 2 mg/L culture (56%). Depending on target and fusion, protein yields are usually in the range of 2–100 mg/L culture (although in this example a maximum of ~25 mg/L fusion protein can be detected).

An analysis of the success by number of disulfide bonds present (shown in Figure 6B) shows reasonable success for all numbers of disulfide bonds tested (between 1 and 7), with the lowest success level being 66% for targets containing 6 disulfide bonds. An analysis of the distribution of expression success based on isoelectric point and number of residues (shown in Figure 6C) shows no particular bias for the technique, with both successfully expressed targets and targets that were not detected scattered throughout the plot.

Figure 6D shows an example of the mass spectrometry results obtained from electrospray ionization mass spectrometry (ESI-MS) for a single target, before and after reduction of the sample with DTT. Normally, such an exhaustive mass spectrometry analysis would not need to be performed (a reduced sample would not need to be analyzed), however for the purposes of thorough demonstration we have shown both results. The target shown is a 5.7 kDa disulfide-rich venom protein with 4 disulfide bonds. The spectrum on the left shows the results for the protein prior to reduction with DTT, as it was after cleavage and desalting without further intervention. The spectrum on the right hand side shows the protein after reduction with DTT followed by desalting to remove any excess DTT. The ions corresponding to the experimental masses are marked with arrows on the spectrum and the designation for each ion is shown in green. The experimental parent masses calculated for these ions (for the protein prior to reduction (-DTT) and after reduction (+DTT)) are shown in the table. The masses (5709.6 Da for the sample prior to reduction and 5717.6 Da for the reduced sample) exhibit a mass difference of 8 Da. A mass difference of 2 Da corresponds to the presence of 1 oxidized disulfide bond, therefore a mass difference of 8 Da indicates the presence of 4 disulfide bonds (as expected) in the non-reduced sample.

Figure Legends:

Figure 1: Schematic representation of the high throughput expression screening protocol. Using this protocol, 96 to 384 conditions can be tested by a single person in one week using manual methods, or up to 1152 conditions with the described semi-automated equipment. Expression plasmids are constructed using a recombination cloning technology so that numerous targets can be sub-cloned at one time. Once soluble expression conditions have been

identified and cleavage performed, if desired, the protein can proceed to quality control to check oxidation and purity, microassays and/or large-scale production.

Figure 2: Schematic for universal recombinational cloning and construct design. From the target entry clones, multiple expression vectors can be sub-cloned in a single experiment in a high throughput fashion (up to 6x96 entry clones in a week). The expressed protein encodes a HIS tag for nickel affinity purification. The DsbC (lacking its periplasmic signal sequence for cytoplasmic expression) fusion partner is used to increase solubility and/or aid folding and correct oxidation of the target protein. Note that the target coding sequence should contain an N-terminal TEV protease site (ENLYFQ) if tag cleavage is desired. The inset at the top left shows the production of the entry clones using a donor vector and the target sequences, which can be obtained by PCR or gene synthesis. Entry clones can also be obtained from commercial entry clone collections. Multiple recombinational cloning systems are available, however we utilize the Gateway system, as shown in the schematic.

Figure 3: High throughput screening pipeline for multiple disulfide-rich targets. Targets are initially expressed as HIS-DsbC fusions in the cytoplasm of BL21 (DE3) pLysS *E. coli* at 37/17 °C using auto-induction medium (ZYP-5052). Purification is performed on nickel resin followed by detection of soluble constructs by HTP electrophoresis (or with dot blot/SDS-PAGE). If the first round of expression screening is unsuccessful, alternative culture conditions are tried. If constructs produce soluble proteins in high enough yields, microassays and quality control can be performed and, if required, large-scale production can be pursued. For targets where soluble yields are not high enough, expression screening can continue with alternative strains and temperatures then other fusion partners and periplasmic expression. Optional steps are indicated by dashed boxes.

Figure 4: Robot Worktable setup for the HTP platform. The layout of our liquid handling robot worktable is shown, although alternative worktables can also be used provided there are equivalent sites available. The setup consists of a wash station (WS) for the (8-channel liquid handling head (LiHa)), two microplate carriers with 4 positions each (MP4, positions 1–4 and 5–8), a vacuum station with 2 positions (Te-VacS, positions 9 and 10), a microplate carrier with 3 positions (MP3, positions 11–13), two plate shakers with 2 positions each (Te-Shakers, positions 14–15 and 16–17) and a carrier for disposable tips with 3 positions (DiTi, positions 18–20). In addition there are two hotel carriers for deep well plates and one for microplates (not shown). The hardware installed on the liquid handling robot is a 96-multichannel arm (MCA96) for use with disposable tips, an 8-channel liquid handling head (LiHa) with fixed tips and a robotic manipulator (RoMa) that moves plates/equipment around on the worktable. The numbering of the positions is referred to throughout the protocol.

Figure 5: Schematic for transferring from a single 96-well plate into four 24-well plates.

Figure 6: Representative results are shown for the expression screen of 96 disulfide-rich venom proteins. The proteins were expressed as HIS-DsbC fusions in the cytoplasm and purified using 50 µl of Nickel resin (Protocol 8.2-B). (A) Expression screening results, showing

virtual gel and scoring for the expression yield. Note that for some targets two bands can be seen, the upper band corresponding to the intact fusion protein and the lower band corresponding to the fusion tag alone. (B) The proportion of proteins expressed at each expression level compared to the number of disulfide bonds in the protein. The actual number of proteins in each group is overlayed on the graph. (C) The distribution of expression levels based on isoelectric point (pI) and number of residues. (D) An example of the mass spectrometry results for a 5.7 kDa disulfide-rich venom protein with 4 disulfide bonds. The spectrum on the left hand side shows the protein prior to reduction with DTT and the spectrum on the right hand side shows the protein reduced with DTT and then desalted. The ions corresponding to the experimental masses are marked with arrows and their assignments are shown in green. The experimental masses for the protein prior to reduction and after reduction are shown in the table and exhibit a mass difference of 8 Da, corresponding to the presence of oxidized protein before addition of reducing agent.

Table 1: Recipe for components of ZYP-5052 medium.

DISCUSSION:

There is no single universal protocol for the expression of soluble, folded, functional proteins. To be cost- and time-efficient, most laboratories or protein core facilities working with multiple targets therefore use high throughput protein expression screening to find the best ‘generic’ combination of variables to obtain a soluble active protein for the majority of targets. We have identified DsbC as being a generally applicable fusion partner for the soluble expression of disulfide-rich peptides and proteins¹¹. Using DsbC fusions and high throughput methods, within a week the soluble expression of multiple targets can be observed¹¹ and then additional variables, such as those discussed in the introduction, can be screened in subsequent rounds on those targets that require further optimization. The protocols described herein are aimed at the expression of disulfide-rich proteins and peptides. However, for users wishing to express non-reticulated proteins in a high throughput manner, the corresponding protocols have been published previously and can be found elsewhere^{22,24}.

The high throughput setup is ideal for a number of applications, including the screening of a large number of different proteins for soluble expression or the screening of a large number of expression constructs (including various fusion tags) for several target genes at the same time (or multiple expression constructs for a single target) in order to improve success rates. The platform can also be used for the benchmarking and validation of new protocols on a large number of targets. Other applications include the screening of variants for a single difficult target, e.g., all orthologs or members of the same family, or to test the success of production of a panel of mutants of a single target in one experiment. This protocol has also been used in combination with co-expression vectors (with one tagged protein only) to allow the pull down and preliminary characterization of protein-protein complexes followed by more thorough biophysical analysis to confirm the correct complex formation and stoichiometry³³. The amount of protein purified is sometimes suitable for micro-assays (functional tests, protein-DNA³⁴ or protein-protein interaction assays³⁵). There are several advantages to the high throughput

expression screening strategy: (i) the ability to test a large number of targets or a large number of variables in a single experiment, (ii) limited batch-to-batch variation, (iii) the simplicity and ease of working at a smaller-scale using deep-wells, (iv) scalability and reproducibility at larger scale, (v) the potential for automation, and (vi) simplicity of tracking and handling (no labeling of individual tubes, less mistakes introduced when using the plate format than with the handling of individual tubes in the mixing or exchanging of clones).

Although not discussed in the protocol section, there are several important considerations for the preparation of the experiment that will be briefly discussed below. For a more thorough discussion please see our previous publication²⁴. For maximum efficiency, it is beneficial to have a suitable system for high throughput cloning, to simplify the sub-cloning of large numbers of targets. For the initial phase of the VENOMICS project, we utilize the versatile Gateway recombination system²⁵ that allows subcloning in any destination vector at a pace of hundreds of clones per week. Protocols for Gateway recombination cloning can be found on the Invitrogen website. Other alternatives for high throughput cloning include ligation-independent cloning (LIC)^{36,37} and restriction-free (RF) cloning³⁸. There are multiple ways to obtain the target genes for expression, including by PCR from template DNA, from entry clone collections or as synthetic genes, which is the strategy chosen for the VENOMICS project. Synthetic genes can be ordered with recombination sites on each end of the gene and gene synthesis allows easy codon optimization of the target gene sequence (to exclude rare *E. coli* codons). This is recommended but not essential. For targets without codon optimization that contain a high number of rare codons, Rosetta 2 (DE3) pLysS (which carries tRNAs for rare codons that are not highly expressed in *E. coli*) may be better suited than BL21 (DE3) pLysS. While there are strains available that limit the reduction of disulfide bonds in the normally reducing environment of the cytoplasm, in our hands they have not been as successful as regular *E. coli* strains¹¹.

Analytical scale affinity purification is performed from the test expression cultures in order to recover the soluble fusion proteins and quantify yields. Quantitative data can be obtained on the soluble yields of fusion proteins expressed within a range of 0.1–100 mg/L of culture. If a target is not soluble, alternative expression and induction temperatures, strains or media can be tested before different fusion partners are pursued. For soluble expression of disulfide-rich proteins, we previously ranked the effect of fusion partners as DsbC > DsbA > GST > MBP > TRX > HIS-tag for cytoplasmic expression¹¹. Periplasmic expression is another possibility that may aid the successful folding of disulfide-rich targets. The periplasm is a less reducing environment than the cytoplasm and contains useful redox chaperones to assist disulfide bonding. DsbC, DsbA, and MBP proteins are normally localized to the periplasm by their periplasmic signal sequences. This provides the opportunity to exploit these tags to direct the disulfide-rich targets to the periplasmic space in order to assist folding. For intractable targets, the next step would be to purify the insoluble HIS-tagged target from inclusion bodies, solubilize and refold (this is out of the scope of this protocol and will not be discussed here³⁹). This can be fairly simple for targets with only one or two disulfide bonds, but becomes increasingly more difficult as the number of disulfide bonds increases. Alternatively, and particularly for proteins and peptides with four or more disulfide bonds, it may be beneficial to try more complex production systems such as yeast, insect or mammalian expression.

With advances in miniaturization and automation, HTP electrophysiology lab-on-a-chip technologies²⁸ will undoubtedly be the way of the future for functional analyses. We envisage that for most purposes (perhaps with the exception of structural studies) this will negate the need for large scale cultures. Small scale cultures will not only be useful for screening expression conditions, but also be able to provide sufficient amounts of sample for these miniaturized functional assays. The ability to produce multiple targets in parallel in sufficient quantities for functional characterization will lower the costs of culturing and using these kind of platforms, expression and characterization of recombinant proteins will become more cost and time-effective.

The protocols herein have been applied to the expression of disulfide-rich peptides and proteins in the initial phase of the FP7 European VENOMICS project. Venoms are an excellent source of bioactive peptides that often have interesting pharmacological potential. However, their production is challenging due to their complex disulfide-bonding patterns and small size. Using high-throughput platforms like the one described herein, the VENOMICS project aims to generate a library of 10,000 novel venom peptides to reproduce the diversity observed in nature. This library will be exploited for the characterization of disulfide-rich peptides with potential pharmacological or therapeutic applications with the aim of developing new drugs. The platform is currently being used for benchmarking and validating new protocols for use in the VENOMICS project.

ACKNOWLEDGMENTS:

This work was supported by The VENOMICS project, European project grant N° 278346 through the Seventh Framework Program (FP7 HEALTH 2011-2015). The VENOMICS project is a collaboration between several research institutions and companies in Europe:

- AFMB, Aix-Marseille Université (France)
- CEA Saclay (France)
- NZYTech (Portugal)
- Sistemas Genomicos (Spain)
- University de Liege (Belgium)
- VenomeTech (France)
- Vitamib (France)
- Zealand Pharma (Denmark)

This work was supported by the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INSB-05-01.

DISCLOSURES:

The authors declare that they have no competing financial interests.

REFERENCES

- 1 Berrow, N. S. *et al.* Recombinant protein expression and solubility screening in *Escherichia coli*: a comparative study. *Acta Crystallographica Section D-Biological Crystallography* **62**, 1218-1226, doi:10.1107/s0907444906031337 (2006).
- 2 Correa, A. & Oppezzo, P. Tuning different expression parameters to achieve soluble recombinant proteins in *E. coli*: advantages of high-throughput screening. *Biotechnol J* **6**, 715-730, doi:10.1002/biot.201100025 (2011).
- 3 Graslund, S. *et al.* Protein production and purification. *Nat Methods* **5**, 135-146, doi:10.1038/nmeth.f.202 (2008).
- 4 Vera, A., Gonzalez-Montalban, N., Aris, A. & Villaverde, A. The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. *Biotechnol Bioeng* **96**, 1101-1106, doi:10.1002/bit.21218 (2007).
- 5 Graslund, S. *et al.* The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. *Protein Expr Purif* **58**, 210-221, doi:10.1016/j.pep.2007.11.008 (2008).
- 6 Bird, L. E. High throughput construction and small scale expression screening of multi-tag vectors in *Escherichia coli*. *Methods* **55**, 29-37, doi:10.1016/j.ymeth.2011.08.002 (2011).
- 7 Davis, G. D., Elisee, C., Newham, D. M. & Harrison, R. G. New fusion protein systems designed to give soluble expression in *Escherichia coli*. *Biotechnol Bioeng* **65**, 382-388 (1999).
- 8 Kapust, R. B. & Waugh, D. S. *Escherichia coli* maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. *Protein science: a publication of the Protein Society* **8**, 1668-1674, doi:10.1110/ps.8.8.1668 (1999).
- 9 LaVallie, E. R., Lu, Z., Diblasio-Smith, E. A., Collins-Racie, L. A. & McCoy, J. M. Thioredoxin as a fusion partner for production of soluble recombinant proteins in *Escherichia coli*. *Methods Enzymol* **326**, 322-340 (2000).
- 10 Marblestone, J. G. *et al.* Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. *Protein science: a publication of the Protein Society* **15**, 182-189, doi:10.1110/ps.051812706 (2006).
- 11 Nozach, H. *et al.* High throughput screening identifies disulfide isomerase DsbC as a very efficient partner for recombinant expression of small disulfide-rich proteins in *E. coli*. *Microb Cell Fact* **12**, 37, doi:10.1186/1475-2859-12-37 (2013).
- 12 Sachdev, D. & Chirgwin, J. M. Fusions to maltose-binding protein: control of folding and solubility in protein purification. *Methods Enzymol* **326**, 312-321 (2000).
- 13 Smith, D. B. Generating fusions to glutathione S-transferase for protein studies. *Methods Enzymol* **326**, 254-270 (2000).
- 14 de Marco, A., Deuerling, E., Mogk, A., Tomoyasu, T. & Bukau, B. Chaperone-based procedure to increase yields of soluble recombinant proteins produced in *E. coli*. *BMC Biotechnol* **7**, 32, doi:10.1186/1472-6750-7-32 (2007).
- 15 Hatahet, F., Nguyen, V. D., Salo, K. E. & Ruddock, L. W. Disruption of reducing pathways is not essential for efficient disulfide bond formation in the cytoplasm of *E. coli*. *Microb Cell Fact* **9**, 67, doi:10.1186/1475-2859-9-67 (2010).

- 16 de Marco, A. Recent contributions in the field of the recombinant expression of disulfide bonded proteins in bacteria. *Microb Cell Fact* **11**, 129, doi:10.1186/1475-2859-11-129 (2012).
- 17 Katzen, F. & Beckwith, J. Disulfide bond formation in periplasm of Escherichia coli. *Methods Enzymol* **348**, 54-66 (2002).
- 18 Klint, J. K. *et al.* Production of recombinant disulfide-rich venom peptides for structural and functional analysis via expression in the periplasm of E. coli. *PloS one* **8**, e63865, doi:10.1371/journal.pone.0063865 (2013).
- 19 Braud, S. *et al.* Dual expression system suitable for high-throughput fluorescence-based screening and production of soluble proteins. *Journal of proteome research* **4**, 2137-2147, doi:10.1021/pr050230i (2005).
- 20 Douzi, B. G. A. *et al.* in *Advances and new technologies in toxinology*. A new system for expressing recombinant animal toxins in E. coli. (Collection Rencontres en Toxinologie, Publications de la SFET, Catenay-Malabry, 2010:149–152).
- 21 Groisillier, A. *et al.* MARINE-EXPRESS: taking advantage of high throughput cloning and expression strategies for the post-genomic analysis of marine organisms. *Microb Cell Fact* **9**, 45, doi:10.1186/1475-2859-9-45 (2010).
- 22 Vincentelli, R. *et al.* High-throughput protein expression screening and purification in Escherichia coli. *Methods* **55**, 65-72, doi:10.1016/j.ymeth.2011.08.010 (2011).
- 23 Xiao, R. *et al.* The high-throughput protein sample production platform of the Northeast Structural Genomics Consortium. *Journal of structural biology* **172**, 21-33, doi:10.1016/j.jsb.2010.07.011 (2010).
- 24 Saez, N. J. & Vincentelli, R. in *Structural Genomics: General Applications, Methods in Molecular Biology vol. 1091* (ed Y.W. Chen) High-throughput expression screening and purification of recombinant proteins in E. coli. Ch. 3 , Humana Press, 33-53, doi: 10.1007/978-1-62703-691-7 (2014).
- 25 Katzen, F. Gateway (R) recombinational cloning: a biological operating system. *Expert. Opin. Drug Discov.* **2**, 571-589, doi:10.1517/17460441.2.4.571 (2007).
- 26 Vincentelli, R., Canaan, S., Offant, J., Cambillau, C. & Bignon, C. Automated expression and solubility screening of His-tagged proteins in 96-well format. *Analytical biochemistry* **346**, 77-84, doi:10.1016/j.ab.2005.07.039 (2005).
- 27 Studier, F. W. Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* **41**, 207-234 (2005).
- 28 Spencer, C. I. *et al.* Ion channel pharmacology under flow: automation via well-plate microfluidics. *Assay Drug Dev Technol* **10**, 313-324, doi:10.1089/adt.2011.414 (2012).
- 29 Sala, E. & de Marco, A. Screening optimized protein purification protocols by coupling small-scale expression and mini-size exclusion chromatography. *Protein Expr Purif* **74**, 231-235, doi:10.1016/j.pep.2010.05.014 (2010).
- 30 Moon, A. F., Mueller, G. A., Zhong, X. & Pedersen, L. C. A synergistic approach to protein crystallization: combination of a fixed-arm carrier with surface entropy reduction. *Protein science: a publication of the Protein Society* **19**, 901-913, doi:10.1002/pro.368 (2010).
- 31 Zanier, K. *et al.* Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. *Science (New York, N.Y.)* **339**, 694-698, doi:10.1126/science.1229934


- (2013).
- 32 Kapust, R. B., Tozser, J., Copeland, T. D. & Waugh, D. S. The P1' specificity of tobacco etch virus protease. *Biochemical and biophysical research communications* **294**, 949-955, doi:10.1016/S0006-291X(02)00574-0 (2002).
 - 33 Vincentelli, R. & Romier, C. Expression in Escherichia coli: becoming faster and more complex. *Current Opinion in Structural Biology* **23**, 326-334 (2013).
 - 34 Jolma, A. *et al.* DNA-binding specificities of human transcription factors. *Cell* **152**, 327-339 (2013).
 - 35 Charbonnier, S. *et al.* High-throughput determination of domain-ligand affinities by automated holdup assay allows quantification of linear motif specificities. (under revision).
 - 36 Aslanidis, C. & de Jong, P. J. Ligation-independent cloning of PCR products (LIC-PCR). *Nucleic acids research* **18**, 6069-6074 (1990).
 - 37 Haun, R. S., Serventi, I. M. & Moss, J. Rapid, reliable ligation-independent cloning of PCR products using modified plasmid vectors. *BioTechniques* **13**, 515-518 (1992).
 - 38 van den Ent, F. & Lowe, J. RF cloning: a restriction-free method for inserting target genes into plasmids. *Journal of biochemical and biophysical methods* **67**, 67-74, doi:10.1016/j.jbbm.2005.12.008 (2006).
 - 39 Vincentelli, R. *et al.* High-throughput automated refolding screening of inclusion bodies. *Protein science: a publication of the Protein Society* **13**, 2782-2792, doi:10.1110/ps.04806004 (2004).




Expression vectors
encoding different targets




Day 1



Transformation
PCR96




Plating
4 x TC24



Preculture
DW96




Day 2



**Small-scale
cultures**
4 x DW24




Day 3/4




Harvest
4 x DW24 into DW96
Lysis and Purification
DW96





Day 4/5



**Solubility
assessment**
SDS-PAGE/dot
blot/Caliper









PCR96 or DW96


	1	2	3	4	5	6	7	8	9	10	11	12
A	1	9	17	25	33	41	49	57	65	73	81	89
B	2	10	18	26	34	42	50	58	66	74	82	90
C	3	11	19	27	35	43	51	59	67	75	83	91
D	4	12	20	28	36	44	52	60	68	76	84	92
E	5	13	21	29	37	45	53	61	69	77	85	93
F	6	14	22	30	38	46	54	62	70	78	86	94
G	7	15	23	31	39	47	55	63	71	79	87	95
H	8	16	24	32	40	48	56	64	72	80	88	96




A




B



C



D



Component	Recipe
ZY	~928 ml 10 g tryptone 5 g yeast extract 925 ml water
2M MgSO ₄	100 ml 49.3 g MgSO ₄ •7H ₂ O ~60 ml water
50X 5052	1 L 250 g glycerol 730 ml water 25 g glucose 100 g α-lactose
20X NPS	1 L 900 ml water 66 g (NH ₄) ₂ SO ₄ 136 g KH ₂ PO ₄ 142 g Na ₂ HPO ₄

Comment
Mix and then autoclave to sterilize.
Stir until dissolved then autoclave to sterilize.
Add in sequence, stir over heat until all dissolved then autoclave to sterilize.
Add in sequence and stir until all dissolved then autoclave to sterilize.

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Tecan Freedom EVO 200 liquid handling robot	Tecan Group Ltd.		Protocols can be adapted to any liquid handling robot with a vacuum manifold for plates.
96-well PCR (PCR96) plates	Greiner Bio-One	652270	
LB medium			Autoclaved for sterility.
Antibiotic stocks			Kanamycin (50 mg/ml), Ampicillin (100 mg/ml), Chloramphenicol (34 mg/ml in ethanol), store stocks at -20 °C. Use a 1 in 1000 dilution.
Deep-well 96 (DW96) plate with 2.42 ml volume capacity	Greiner Bio-One	780270	Autoclaved for sterility.
Expression vectors			For the expression of target constructs. Store at –20 °C.
BL21 (DE3) pLysS competent cells			Or alternative <i>E. coli</i> expression strain of the user's choice. Store at –80 °C.
Breathseal breathable adhesive film	Greiner Bio-One	676050	
PCR machine with 96-well plate block			For the transformation heat shock and boiling of SDS-PAGE/Caliper samples.
24-well sterile tissue culture plates	Greiner Bio-One	662165	
LB-agar			Autoclaved for sterility.
200 µl sterile disposable tips	Tecan Group Ltd.	30 038 617	
Multitron Shaking Incubator, with 3 mm throw	Infors	AJ103	Not essential, a regular shaking incubator can also be used.
Plate incubator			
Microtiter plate			For glycerol stocks and elution using purification protocol B.
Glycerol			For the preparation of glycerol stocks.
200 µl disposable tips	Tecan Group Ltd.	30 038 616	
Adhesive tape pads	Qiagen	19570	
Bactinyl	Orapi Group		Or equivalent microbial disinfectant.
ZYP-5052 medium			See Table 1 for recipes of components.
Deep well 24 (DW24) plates,10 ml capacity	Whatman	7701-5102	Autoclaved for sterility.
Flat-bottomed, clear microtiter plate	Greiner Bio-One	655101	For absorbance readings.
Plate reading spectrophotometer			Optional. For measuring OD _{600nm} of cultures.
Centrifuge with rotor for deep well plates			Suitable for 3800 x g.
Lysozyme			50 mg/ml in water. Store at –20 °C.
Imidazole ACS grade	Merck	IX0005-1	A high quality grade of imidazole must be used so that it will not interfere with A ₂₈₀ readings for calculating protein yield.
Lysis buffer			50 mM Tris, 300 mM NaCl, 10 mM imidazole pH 8 containing 0.25 mg/ml lysozyme (or your preferred buffer). Add lysozyme from stocks each time and do not store for extended periods.
Water bath			
Plate sonicator (Ultrasonic processor XL, adapted for deep well plates)	Misonix Inc.		Not essential. Lysozyme alone is normally sufficient for nearly complete lysis.
DNase			2 mg/ml stock in water, filter sterilized. Store aliquots at –20 °C.
Magnesium sulphate (MgSO ₄)			2M stock in water, autoclaved.
SDS-PAGE or Caliper sample buffer			
Binding buffer			50 mM Tris, 300 mM NaCl, 10 mM imidazole pH 8 (or your preferred buffer). Store at 4 °C.

Wash buffer			50 mM Tris, 300 mM NaCl, 50 mM imidazole pH 8 (or your preferred buffer). Store at 4 °C.
Elution buffer			50 mM Tris, 300 mM NaCl, 250 mM imidazole pH 8 (or your preferred buffer). Store at 4 °C.
96-well Receiver/Filter Plate 20 µm, 1.8 ml capacity	Macherey-Nagel	740686.4	
200 µl disposable wide bore tips	Tecan Group Ltd.	30 050 348	
Ni Sepharose 6 Fast Flow resin	GE Healthcare	17-5318-02	For purification of target fusion proteins. Store at 4 °C. Wash and equilibrate before use.
Tobacco Etch Virus (TEV) protease			Optional, for cleavage. 2 mg/ml, without reducing agents in storage buffer. Store at -80 °C.
96-well 0.22 µm filter plate	Millipore	MSGV N22 10	Optional. To filter the soluble fraction after cleavage.
SDS-PAGE/dot blot equipment or Caliper Labchip GXII equipment			Electrophoresis apparatus and choice of gel type is at the user's discretion.
Spectrophotometer and cuvettes			For measuring absorbance at 280 nm (A_{280}) to calculate yield of soluble proteins. Not required if the analysis is done on the Caliper.
ZipTip pipette tips	Millipore		Optional. The type of ZipTip is at the user's discretion. C4 resin should be used for larger proteins, while for peptides C18 may be better. Alternative methods for desalting of samples may also be used to clean up samples before further quality control.
Reagents, Equipment & Safety			
Materials are listed in the order in which they are required in the Protocol section. Reagents can be stored at room temperature unless noted otherwise. Reference numbers for the author's preferred choice of materials are provided, however equivalent products may also be suitable. For reagents where the brand will not influence the outcome of the experiment, the company details have been omitted.			



17 Sellers Street
Cambridge, MA 02139
tel. +1.617.945.9051
www.JoVE.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: High throughput cloning, quantitative expression screening and analytical affinity purification of disulfide-rich proteins and peptides in E. coli

Author(s): Saez, NJ., Nozach, H., Blemont, M. & Vincentelli, R.

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the

ARTICLE AND VIDEO LICENSE AGREEMENT

Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict

shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including,

ARTICLE AND VIDEO LICENSE AGREEMENT

without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or

damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

AUTHOR:

Name: Renaud Vincentelli
Department: Architecture et Fonction des Macromolécules Biologiques (AFMB)
Institution: Aix Marseille Université, Marseille, France
Article Title: High throughput cloning, quantitative expression screening and analytical affinity purification of disulfide-rich proteins and peptides in E. coli

Signature:



Date:

24/07/2013

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy as a PDF to the JoVE submission site upon manuscript submission (preferred);
- 2) Fax the document to +1.866.381.2236; or
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 17 Sellers St / Cambridge, MA 02139

For questions, please email editorial@jove.com or call +1.617.945.9051.

MS # (internal use):

Centre National de la Recherche Scientifique
Aix-Marseille Université
CNRS UMR 7257, AFMB
163 Avenue de Luminy
13288 Marseille, France

Marseille, 11th of December 2013.

Dear Dr Buntrock,

RE: Submission JoVE51464R2

Please find below our responses to the peer-review for our manuscript JoVE51464R2 entitled “High throughput quantitative expression screening and purification applied to recombinant disulfide-rich venom proteins produced in *E. coli*”.

We thank the reviewers for their constructive comments and we have incorporated them into the manuscript where suitable. Each of the reviewer comments are addressed in further detail below (our responses are shown in blue).

Reviewer #1:

Major Concerns:

My major criticism is that it took me too much effort trying to piece together the different steps of the described protocols. For clarity, at each step, please indicate the source and destination plate names and/or positions on the robot worktable. For example, the transformation mix indicated in step 1.3 of the "Precultures and plating" protocol has never been mentioned before (does it correspond to DW96 at position 11 ?). Also the role of the transformation plate at position 13 in step 1.1.3 is not defined.

The positions on the robot worktable for the source and destination plates at each step have been defined to avoid confusion in the protocols. The transformation mix comes from the manual transformation protocol. The origin of the transformation mixes and their role in the protocol are now more clearly stated.

Minor Concerns:

1. Page 3 paragraph 2 - "high throughput manual approach". When it comes to manual I would be more cautious not to use the high-throughput qualifier.
The phrase high throughput manual approach could be removed and replaced by “can also be used manually to improve efficiency’ but as stated in the same paragraph one can achieve 96/384 points/week with manual protocols which can be considered HTP by many labs so we left it as it is for the time being. If the editor wants the substitution of text can be done.
Page 4 paragraph 1 - "in all constructs proteins are cloned" please correct!
This has been fixed.
2. Last sentence of paragraph 6 need to be rephrased
The sentence has been rephrased.
3. Page 5 intro - manually instead of "in a manual way"
This has been adjusted.
4. Page 5 - section 1.1.3 needs to be rephrased for clarity. A section 1.1.4 ?
Step 1.1.3 has been better defined for clarity. The authors do not believe that a Step 1.1.4 is required.
5. Page 8 section 6.4 - please rephrase for clarity
This has been rephrased for clarity.

6. Page 9 section 7.3 - "after which stage" please rephrase
This has been changed to 'at this point'.
7. Page 12 section 8.2.5 - Please indicate the temperature of incubation. Also either 700 or 1200 ul according to steps 8.1.14 & 15
The temperature of incubation has been included in Step 8.2.4.
For the nickel affinity purification, there are two options for the protocol. Either the use of 200 ul final volume of resin (which is Section 8.1 – Protocol A) or the use of 50 ul final volume of resin (which is Section 8.2 – Protocol B). The protocols are independent of each other, and only one of the two protocols is performed in any one experiment. This is detailed in the introduction. Accordingly, for Step 8.2.5, the volume is 1200 ul (1000 ul of lysate + 200 ul of resin slurry). Step 8.1.14 and 8.1.15 have no influence over the volume at Step 8.2.5.
8. What does "normal 200 ul tips" mean ?
The 'normal' has been removed from the text. In this case, it just meant 'not wide-bore tips', but it is redundant and therefore was removed.
9. Page 13 section 9.4 - Please rephrase
Step 9.4 has been rephrased for clarity.
10. Page 13 section 10.1.1 - Not clear. Please rephrase
Steps 10.1.1- 10.1.4 have been clarified.
11. Page 16 Discussion paragraph 1 - most laboratories
This change has been made.
12. Page 16 Discussion paragraph 1 - "Using this approach,..." Reformulate this sentence and be more precise concerning the additional variables. A reference ?
The additional variables to be optimized have already been discussed in the introduction, therefore we have directed the reader to the introduction regarding the precise list of variables and their relevant references. The sentence "Using this approach..." has been reformulated. It is now: 'Using DsbC fusions and high throughput methods, within a week the soluble expression of multiple targets can be observed¹¹ and then additional variables, such as those discussed in the introduction, can be screened in subsequent rounds on those targets that require further optimization.'

Reviewer #2:

Minor Concerns:

1. Figure 4 is missing from the revised ms.
To the best of our knowledge, Figure 4 was included in the manuscript. Other reviewers had comments on Figure 4, so we believe the figure was included.
2. Although the article is entitled " High throughput quantitative expression..." The exemplification of the method is limited to 2 proteins only which would not require HTP/automation to produce. It would be helpful for results for a full 96 well plate experiment to be shown so that the quality of data from the protocol could be seen.
We have significantly changed our representative results to incorporate the results seen from a screen on a full set of 96 samples.
3. The mass spec analysis should be shown for the examples since in one case no cleaved product is seen on the SDS-PAGE.
We have now provided an example of a mass spec analysis as part of the representative results.

Reviewer #3:

Major concerns:

The paper does not contain much new Information that has not been published: The most helpful tag (i.e. the DsbC gene product) is described in other studies and the same holds true for the expressed targets. Gateway cloning (Invitrogen) is a well-established but expensive technique. This submission contains no results with exception of two of the "representative" proteins (Figure 6). I am aware that JoVe is a methods journal, but I feel that at least some data supporting the validity of the statements about the techniques have to be included in any method paper. A few general comments are just not enough. It is the substantial lack of data confirming the usefulness of the techniques which is the serious shortcoming of the paper. A wider readership would also appreciate some data to give a better feeling of the value of the DsbC tag in conjunction with larger more commonly used proteins. A laboratory with a good reputation for high-throughput work (and the lab in Marseille is well known for its HTP-achievements) can and should provide direct evidence to allow a serious judgment of the claims inside the publication. Thus, without addition of quite a few more data (at least a table giving a considerable number of purifications with the ratio of successful/failed plus the pI and lengths of the targets), I consider this paper not suitable for publication. Right now it looks more like a copy of a set of detailed lab protocols.

Editorial Comment: Considering JoVE is a methods journal, we do not require that you add any additional data to your manuscript. However, if you believe the addition of the data suggested by the above reviewer will significantly improve your manuscript, please add it to your manuscript.

Our representative results section and figure have been reworked to include the analytical expression results for a full 96 targets. We hope that the data provided now demonstrate more thoroughly the effectiveness of the technique. Additionally, we have also provided the number of disulfides, number of residues and isoelectric point for each target and included these in our analysis of results.

For the wider readership not interested by the expression of animal venom peptides, we have also included a sentence regarding our previous publication that states that the disulfide rich proteins screened previously not only came from venomous sources, but also included disulfide-rich enzyme inhibitors from a wide range of species including plants, pigs, cows and humans.

Minor Concerns:

See Manual remarks in attached or mailed PDF file; pages without comments are not shown.

Editorial Comment: Please see the attached PDF "PR#3comments to JoVE51464R2."

Typographical errors as well as suggestions highlighting a lack of clarity or for improved delivery have been adjusted accordingly.

The sections highlighted in yellow are required by JoVE as a guide to which parts of the protocol we wish to demonstrate in the associated video.

With regards to the Table of Materials/Equipment, this was submitted to JoVE as an excel file and the formatting problems seem to have appeared upon conversion to pdf format, as they are not present in the original excel document.

Additional Comments to Authors:

In all other aspects the method is well presented and written. I think it can be reproduced in a laboratory with HTP equipment and even in a lab with less high-tech apparatus. Some of the description may be too detailed, especially Figure 5 (transfer from 96- to 24-well plates). I suggest dropping this figure. The autoinduction media are published in much detail in reference 27; the Table 1 (taking 2 pages) describing this technique is probably not necessary in large format. The less important details are given in the accompanying pdf file with my hand-written comments. Pages without comment are not included. Some are just language or typos while others are minor suggestions to the authors.

Editorial Comment: You may maintain the current level of detail in your manuscript as the purpose of a JoVE article is to provide a detailed account of your methods to both specialists and non-specialists.

For the purposes of making the protocols accessible to people outside the field of analytical protein expression, and to have all the relevant information available in one 'go-to guide', we have decided to leave the current level of detail in the manuscript including all figures and tables. Table 1 (submitted as an excel file to JoVE) was not intended to take 2 pages, and this will need to be adjusted for the final publication.

Reviewer #4:

Minor Concerns:

1. The second paragraph of the abstract is difficult to read and deserves some polishing. Similarly, the penultimate paragraph on p.4 ("As a general rule ... on the protein tested") is unclear and should be rewritten.
Both paragraphs have been re-written for improved delivery and clarity.
2. In the first paragraph p.3, the authors mention published work (ref.11), but the main conclusions of this work are not summarized. These conclusions should be briefly provided to ease the reading of the rest of the paragraph without reading the manuscript cited.
We have briefly summarized our results by including the sentence: "We demonstrated that using DsbC as a fusion partner for production in the strain BL21 (DE3) pLysS vastly outproduced (in both yield and number of soluble proteins obtained) any other combination of strain and fusion tested¹¹."
3. End of 2nd paragraph p.3, the text refers to a protocol detailed in Fig.3. It is difficult to understand why this particular protocol has been chosen, this should be clarified.
We have added the sentence: "The parameters in the pipeline were selected based on extensive screening experiments^{11,22}, which allowed us to choose the most useful conditions for protein production."
4. Detailed protocol 3.3 (p.7). The authors mentioned that glucose is depleted after 4 hours in the auto-induction media. Does this information come from their experience and/or from published work? This should be mentioned.
We have added a reference to this step, and also at Step 3.4 added, "... providing the optimal growth conditions for BL21 (DE3) pLysS or Rosetta 2 (DE3) pLysS, in our hands²²."
5. Detailed protocol 8 (p.9-12). The imidazole concentrations indicated in the various buffers are tailored for nickel affinity purification. This should be clearly mentioned, indicating that these concentrations should be adapted when using other ions (e.g. cobalt).
In the note at the beginning of Section 8 we have inserted the sentence: "For purification, the specified imidazole concentrations are applicable to nickel affinity resin. If alternative ions (eg. cobalt) are used, then the concentrations should be adjusted accordingly."
6. Detailed protocol 10 (p.13-14). The authors forget to mention that proteins might stick to or precipitate on the affinity beads upon imidazole elution, a phenomenon that is not uncommon. The authors should address this point and suggest alternative strategies (e.g. resuspend affinity resin with Laemmli buffer followed by SDS-PAGE analysis). This should help identify expression/purification conditions that could be improved by possibly slightly changing expression/purification parameters, rather than discarding the clone used (false negative).
This point is now covered in Step 10.1.3.
7. Detailed protocol 10.1.2 (p.13). Relating to the above comment (6), analysis of whole cell lysates may not be good at observing poorly expressed proteins that will only be detected upon concentration on affinity resin. Once again, sticking/precipitation of this protein to/on the affinity beads will lead to a false negative.

This point is now covered in Step 10.1.3.

8. The word "Unfortunately" should be removed at the beginning of the discussion.

This has been done.

9. In the discussion or earlier in the detailed protocol, alternatives to imidazole elution such as cleavage of the affinity tag directly on the beads should be mentioned. The purified protein obtained using this approach is often purer than the one obtained by increasing imidazole concentration, and is possibly also better suited for subsequent biochemical and biophysical characterizations.

In the introduction text, p4, paragraph 1, when discussing the options for construct design and cleavage, we have mentioned that cleavage can be tested on the elution fraction or 'on column'. As cleavage is only an optional step in the protocol, we have refrained from an in-depth discussion of the issue, so as to not bombard and deter the reader with too many options.

10. Analysis of protein/protein interactions by co-expression in *E. coli* could be performed using the same protocol. This should be mentioned/detailed in the discussion.

The use of the protocol for protein-protein interactions by incorporating co-expression has been included in the discussion with the reference:

Vincentelli, R. & Romier, C. Expression in *Escherichia coli*: becoming faster and more complex. *Current Opinion in Structural Biology* **23**, 326-334 (2013).

More references have also been included for protein-protein and protein-DNA interactions:

Charbonnier, S. *et al.* High-throughput determination of domain-ligand affinities by automated holdup assay allows quantification of linear motif specificities. (under revision).

Jolma, A. *et al.* DNA-binding specificities of human transcription factors. *Cell* **152**, 327-339 (2013).

11. The authors mention several times in their manuscript that scale-up is normally straightforward from their small-scale analysis. This is not what is often observed in different laboratories. The authors should discuss whether this is based on their own experience with the protocol described.

We have further clarified this in the introduction, saying that 'In our experience, the strategy also gives good reproducibility upon scale-up using the same culture (temperature, media, aeration etc.) and purification conditions (same resin, buffers etc.).

12. In Fig.2 and its legend, the method used to go from the entry to the final expression clones is not described; is this Gateway LR reaction? In addition, does clonase means BP Gateway reaction?

JoVE discourages the use of commercial language, therefore we have had to keep mention of the Gateway system to a minimum. We do use the Gateway system, and this is now mentioned in the figure legend for Figure 2. Rather than referring to Gateway cloning directly throughout the text, we refer to recombinational cloning instead, however this is a general moniker, which Gateway cloning falls under. Figure 2 has now been modified so that it says 'enzyme' instead of 'clonase'. In terms of Gateway cloning, the inset in the top left shows the BP reaction, where the enzyme is BP clonase, then the main reaction shown (His-DsbC vector + enzyme + entry clone) is the LR reaction, where the enzyme is the LR clonase. Given that there are various methods for recombinational cloning, we have omitted these specifics in the figure.

13. In Fig.3 the word "again" is not self-explanatory. Please clarify.

The word again has been removed and replaced by 'after trying other strains and temperatures'.

14. Fig.4 and its legend are also not self-explanatory. What is described here? Please clarify.

Figure 4 is a schematic representation of the work table layout for our liquid handling robot. The legend has been adjusted to give a more thorough explanation of what is shown and the function of each module shown. The numbers displayed in the figure correspond to the positions we refer to throughout the protocols.

Thank you for your time and consideration of our manuscript.

Sincerely,

Natalie Saez and Renaud Vincentelli